RENOVA Expands Intellectual Property Portfolio For Cardiovascular And Metabolic Disease Treatments

Renova Therapeutics(hereinafter referred as “Renova”) founded in 2009 and headquartered in San Diego, California, a biopharmaceutical company develops gene therapy treatments for congestive heart failure (CHF) and other chronic diseases The Company also provides gene therapies in pre-clinical stage for those who suffer from Type II diabetes.

Reportedly, Renova has obtained an exclusive worldwide license to a urocortin 3 gene patent from the non-profit Research Development Foundation (RDF) and plans to research this therapeutic gene with the intention to create paracrine gene therapy treatments for patients with cardiovascular diseases such as heart failure. Reportedly, previously this year only, it has also entered into a worldwide exclusive license agreement for RDF’s patent portfolio of urocortin and stresscopin genes, as well as select peptides and proteins with the intention to explore use of this family of genes to create treatment for patients suffering from cardiovascular and metabolic diseases, with one of the world’s most common, incurable and expensive chronic diseases – type 2 diabetes.

 More than 28 million people globally are affected by heart failure and it is the only cardiovascular disease that is increasing in prevalence. It is the most common cause of emergency hospital admissions in patients with age 65 and older. Also, the incidence of type 2diabetes is staggering and growing rapidly, with 27.6 million people in the United States and approximately 370 million people around the world living with this debilitating disease.

This expansion of IP portfolio with RDF would permit Renova to expand inventive research in gene therapy resulting in empowerment for its­ paracrine gene therapy pipeline. Renova Therapeutics’ paracrine gene therapy treatments are based on a novel systemic approach that introduces therapeutic genes capable of leading the body’s cells to work more normally. This exclusive license approach exploits the use of peptide genes that possess favourable cardio-metabolic effects via their paracrine activity. This single-IV-injection treatment method is a base for future products that have the potential to fetch permanent improvements in heart failure and type 2 diabetes patients.

Definitely, patients suffering from CHS and other chronic diseases like type 2 diabetes will have profoundly positive effects on their health in near future as an outcome of Renova Therapeutics’ expansion of IP portfolio.

About the Author: Dr. Komal Tomar, Sr. Licensing Associate at IIPRD and Khurana & Khurana, Advocates and IP Attorneys and can be reached at commercialization@iiprd.com

Tagged

RENOVA

Leave a Reply

Archives

  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010